Nxera Pharma’s target price has been cut. The reduction reportedly reflects a higher DCF discount rate, according to DZH Individual Stock Information. The article was distributed by Jiji Press.
Reports have indicated that Nxera Pharma’s target price has been cut. Although the specific figure is not provided in the article, the key point is that the valuation has been reviewed.
The reduction reportedly reflects an increase in the discount rate used in the DCF (discounted cash flow) model. This may have resulted in a downward revision to the company’s valuation.
The information was distributed as DZH Individual Stock Information and is based on information from Jiji Press. The article was carried by Yahoo! Finance.